FDA approves Dupixent (dupilumab) as treatment for chronic rhinosinusitis
Chronic rhinosinusitis (CRS) is a clinical condition characterized by prolonged inflammation of the nose and paranasal sinuses which lasts for more than 12 weeks. Signs and symptoms of sinusitis include […]
Posted on